FDA Grants Expanded Use of Promacta for Novartis
ThinkstockNovartis AG (NYSE: NVS) is one of the few companies with good news on a major market sell-off. Unfortunately, it is not big enough news to be moving the shares. The Swiss drug giant…
ThinkstockNovartis AG (NYSE: NVS) is one of the few companies with good news on a major market sell-off. Unfortunately, it is not big enough news to be moving the shares. The Swiss drug giant…
ThinkstockVital Therapies Inc. (NASDAQ: VTL) was last seen trading down 80% at $3.41 (versus $17.68 close) after it said that its Phase 3 trial in AILD (alcohol-induced liver decompensation) failed. Vital Therapies was downgraded…
ThinkstockAt a time when there is pressure on how large US companies are making domestic or overseas acquisitions are coming under more scrutiny, Pfizer Inc. (NYSE:PFE) announced on Monday that the Federal Trade Commission…
Over the past week, a few pharmaceutical companies made absolutely massive runs.
Medequities Realty Trust has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering.
Eli Lilly shares got a solid boost in the market Thursday morning as the broad markets were selling off.
Applied Genetic Technologies announced that the Biogen equity investment as part of their collaboration has closed.
ThinkstockWith biotech and specialty pharmaceutical stocks, catalysts and binary events can drive the stocks much higher, or in some cases much lower if the outcome is not what Wall Street was looking for. A…
The Wall Street Journal reported Thursday morning that Canada-based Valeant Pharmaceuticals is preparing to pay $1 billion for the closely held Sprout Pharmaceuticals.
Corbus Pharmaceuticals may have found its saving grace in a Fast Track designation from the U.S. Food and Drug Administration (FDA).
Privately held start-up Sprout Pharmaceuticals received FDA approval on Tuesday for its flibanserin pill with the trade name Addyi.
ThinkstockOmeros Corp. (NASDAQ: OMER) is flying high in Tuesday’s trading session with shares practically doubling on positive phase 2 news. The company announced additional positive data in the it’s phase 2 clinical trial of…
ThinkstockEsperion Therapeutics, Inc. (NASDAQ: ESPR) had a huge move in Monday’s trading session as the result of an analyst upgrade but it looks like this company has kept the rally alive into Tuesday with…
ThinkstockWith a very nervous market, and the end of summer doldrums upon us, it may be time to look for ideas that will make sense when the market heats back up in the fall.…
ThinkstockAclaris Therapeutics, Inc. filed an S-1 form with the Securities and Exchange Commission (SEC) for its initial public offering (IPO). There were no terms given for the filing but the offering is valued up…